Egetis is an innovative and integrated pharmaceutical company, focusing on projects in late-stage development for commercialization for treatment of serious diseases with significant unmet medical needs in the orphan drug segment.

Emcitate® (tiratricol)

Our lead product candidate

Pipeline

Corporate presentation

Press Releases

Regulatory

April 21, 2026

Egetis Therapeutics has successfully carried out a directed share issue amounting to SEK 350 million (approximately USD 38 million)

Read more

Regulatory

April 21, 2026

Egetis Therapeutics announces the intention to carry out a directed share issue of approximately SEK 350 million (approximately USD 38 million)

Read more

Regulatory

April 14, 2026

Bulletin from Egetis Therapeutics’ Annual General Meeting 2026

Read more

Upcoming event

April 29, 2026

Interim Report Q1 2026 webcast (10:00 am CEST)

Latest presentation

March 11, 2026

Leerink Global Healthcare Conference

Latest Report

February 26, 2026

Full year report 2025

Calendar and upcoming reports

April 29, 2026 (7:00am CEST)

Interim Report Q1 2026

Joshua’s Story

Share

Contact us

Address: Klara Norra Kyrkogata 26, SE 111 22 Stockholm, Sweden

Phone: +46 8 679 72 10

E-mail: [email protected]